Nova Distributors, LLC
Letter data
- Company
- Nova Distributors, LLC
- Recipient
- Donald E. Bruch | Nova Distributors, LLC | One Nova Way | R.R. 1 Box 52 | Golden Eagle | , | IL | 62036 | United States | info@tarbarfilter.com
- Issue date
- 2018-02-20
- Posted date
- Not available
- FDA office
- Center for Tobacco Products
- Subject
- Not available
- Product
- Tobacco
- CMS ID
- 539670
- Reference number
- Not available
- FEI
- Not available
- Inspection dates
- Not available
Normalized citations
21 CFR: None found
21 U.S.C.: None found
Related FDA links
No related FDA letter link is present in the source index.
Full source text
CLOSEOUT LETTER
Nova Distributors, LLC
MARCS-CMS 539670 —
February 20, 2018
More Warning Letters
Warning Letters
About Warning and Close-Out Letters
Delivery Method:
VIA UPS and Electronic Mail
Product:
Tobacco
Recipient:
Recipient Name
Donald E. Bruch
Nova Distributors, LLC
One Nova Way
R.R. 1 Box 52
Golden Eagle
,
IL
62036
United States
info@tarbarfilter.com
Issuing Office:
Center for Tobacco Products
10903 New Hampshire Avenue
Silver Spring
,
MD
20993
United States
Dear Mr. Bruch:
On November 17, 2017, the United States Food and Drug Administration's (FDA) Center for Tobacco Products (CTP) issued you a Warning Letter for the sale or distribution of modified risk tobacco products without an FDA order in effect that permits such sale or distribution, in violation of section 911 of the Federal Food, Drug, and Cosmetic Act (FD&C Act).
On December 21 , 2017, you sent FDA a response to the Warning Letter, and we had a teleconference on January 17, 2018 to discuss the Warning Letter and your response. In response to the Warning Letter, you stated that you implemented corrective actions to address the violations identified in the Warning Letter.
Based on our evaluation, it appears that you have taken steps to address the violations identified in the Warning Letter. This letter does not relieve you or your firm from the responsibility of taking all necessary steps to ensure sustained compliance with the FD&C Act and its implementing regulations or with other relevant legal authority. This letter also will not preclude any regulatory action should violations be observed in the future.
Should you have any questions or concerns, please contact Ele Ibarra-Pratt at
(301) 796-9235
or by email at
elenita.ibarrapratt@fda.hhs.gov
.
Sincerely,
/S/
Ann Simoneau, J.D.
Director
Office of Compliance and Enforcement
cc:
Azim Chowdhury
Keller and Heckman, LLP
1001 G Street, N.W.
Suite 500 West
Washington, D.C. 20001
chowdhury@khlaw.com
Content current as of:
05/07/2019
Regulated Product(s)
Tobacco